The deal provides Gilead access to Immunomedics’ breast cancer treatment drug, Trodelvy, which was granted an accelerated FDA approval in April. Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share in cash. …read more
Source:: Yahoo Finance
